Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dishman Carbogen Amics's revenue for the
three
months ended in Jun. 2026 was ₹678 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ₹22,916 Mil.
Dishman Carbogen Amics's Revenue per Share for the
three
months ended in Jun. 2026 was ₹4.32.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹146.17.
During the past 12 months, the average Revenue per Share Growth Rate of Dishman Carbogen Amics was 8.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Dishman Carbogen Amics's highest 3-Year average Revenue per Share Growth Rate was 56.40% per year. The lowest was 1.60% per year. And the median was 7.45% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540701 vs VRTX, REGN, MRNA: Revenue Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's Revenue distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹22,916 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dishman Carbogen Amics (BOM:540701) has a Revenue of ₹22,916 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Dishman Carbogen Amics and its competitors.
Is Dishman Carbogen Amics' Revenue too high?
Dishman Carbogen Amics' current Revenue is ₹22,916 Mil. Overall, Dishman Carbogen Amics has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' Revenue compare to VRTX and REGN?
Dishman Carbogen Amics' Revenue of ₹22,916 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Dishman Carbogen Amics and its competitors. Dishman Carbogen Amics's current Revenue is ₹22,916 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (BOM:540701) is currently considered Fairly Valued. The stock's GF Value™ is ₹182.71, compared to a current price of ₹169.90 — trading 7% below its estimated fair value. The current Revenue is ₹22,916 Mil. Dishman Carbogen Amics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Dishman Carbogen Amics (BOM:540701), the current Revenue is ₹22,916 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (BOM:540701) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹169.90 is trading 7% below its estimated GF Value™ of ₹182.71.
GuruFocus considers Dishman Carbogen Amics to be Fairly Valued.
Key valuation signals for BOM:540701:
Revenue: ₹22,916 Mil
GF Value™: ₹182.71 vs. price of ₹169.90 (7% below fair value)
No single metric tells the full story. See the BOM:540701 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amcis Ltd is an Indian contract development and manufacturing organization (CDMO) serving pharmaceutical and biotechnology companies. It provides process development, scale-up, and commercial manufacturing of active pharmaceutical ingredients (APIs), intermediates, and advanced drug intermediates, along with niche products such as vitamin D3 analogues, cholesterol, and quaternary ammonium compounds used in disinfectants and personal care. The company operates through segments including CDMO, specialty chemicals, quats, and vitamins/cholesterol derivatives. Its customers include global pharmaceutical, generic, and life-science firms that outsource development and manufacturing. Operations and manufacturing sites are located in India and Europe, with sales across Europe, North America, India, China, and other international markets. Revenue is generated primarily through long-term CDMO contracts and product sales, with a significant share derived from European and other overseas markets.
65GF Score
Get the complete analysis for BOM:540701
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540701 has been successfully added to your 
